Synthetic Biologics

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Thursday, October 16, 2014

Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company’s statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).

[Read More]

Synthetic Biologics, Enterome Bioscience collaborate

Wednesday, June 11, 2014

Synthetic Biologics, a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience, a developer of innovative disease management solutions based on a deep understanding of the gut microbiome, have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

[Read More]

Synthetic Biologics raises $10.8M financing

Tuesday, October 30, 2012

Synthetic Biologics, an Ann Arbor, Mich.-based biotech that develops of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, has entered into definitive stock purchase agreements with accredited investors to raise approximately $10.8 million in a private placement financing.

[Read More]

Synthetic Biologics, Intrexon collaborate on infectious diseases

Wednesday, August 8, 2012

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic biologics and innovative medicines for unmet medical needs, and Intrexon, a Germantown, Md.-based synthetic biology company that provides control over cellular function, have entered into a second worldwide exclusive channel collaboration through which Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies.

[Read More]